ArticleClinical rheumatology2018
Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Treat-to-target in Behçet syndrome.Nature reviews. Rheumatology · 2026Review
- Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.EULAR rheumatology open · 2026Article
- Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.Frontiers in ophthalmology · 2024Review
- Shaping the Future of Behçet's Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies.Ophthalmology and therapy · 2023Review
- Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.International ophthalmology · 2023Article
- Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis.Ophthalmology and therapy · 2023Article
- Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study.Frontiers in medicine · 2023Article
- The Application of Artificial Intelligence in the Analysis of Biomarkers for Diagnosis and Management of Uveitis and Uveal Melanoma: A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.Scientific reports · 2020Article
- Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome.Inflammopharmacology · 2020Article
- New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview.Frontiers in pharmacology · 2020Review
- Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience.Mediators of inflammation · 2020Article
- Behçet's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments.Internal and emergency medicine · 2019Article
- Vascular Behçet's syndrome: an update.Internal and emergency medicine · 2019Review
- Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects.Clinical and experimental immunology · 2019Review
- Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.Clinical rheumatology · 2019Observational
- Treating the Different Phenotypes of Behçet's Syndrome.Frontiers in immunology · 2019Review
- Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study.Mediators of inflammation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behçet's disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-α blockers infliximab and adalimumab. Patients still continuing TNF-α inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit. Forty-five patients (75 eyes) were enrolled. Thirty-two patients continued anti-TNF-α treatment for more than 48 months; 13 patients discontinued the treatment after a mean time of 12.3 ± 10.44 months due to lack (61.5%) or loss (38.5%) of efficacy. Baseline value of BD current activity form was the only variable discriminating long- and short-term responsive patients (p = 0.048, OR = 0.656, C.I. 95% 0.433-0.996). Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.